ARCHIVES

In Brief: FDA Opens Advisory Committee Consideration Of NDAs, Finds Discussion Is Not Inhibited

This article is from The Cancer Letter archive.

Vol. 02 No. 37 | September 10, 1976

Download PDF Visit The Full Archive

Related Articles

DCT Board Sends Letter Opposing Bill Requiring Research On RU 486

November 13, 1992

ODAC Reviews Post-Marketing Studies for Eight Indications

March 21, 2003

In Brief: Appropriations Bill Markups Due This Month, With Increases Seen For NCI, NIH, And AIDS

July 3, 1987

Obama Executive Order Gives FDA Authority To Combat Drug Shortages

November 4, 2011

Lilly Suspends Phase III Trial Of Tasisulam in Melanoma

January 28, 2011

In Brief: House Money Bill Reportedly Will Not Increase

September 18, 1981